James C. Mullen

James C. Mullen is an American business executive best known for his long tenure as the chief executive officer of the biotechnology firm Biogen. He played a pivotal role in transforming the company from a research-focused entity into a global commercial leader in neurology, overseeing the development and launch of several major therapies. His leadership spanned a period of significant growth and consolidation within the biotechnology industry.

Early life and education

James C. Mullen was born in 1954. He pursued his undergraduate education at the University of Massachusetts Amherst, where he earned a degree in microbiology. He furthered his studies in the field by obtaining a Master of Science in biochemical engineering from the University of Massachusetts Lowell. This academic foundation in the life sciences provided a critical basis for his subsequent career in the pharmaceutical industry.

Career

Mullen began his professional career at the multinational healthcare company Johnson & Johnson, gaining early experience in manufacturing and operations. He later joined the pharmaceutical firm Baxter International, where he held various positions of increasing responsibility. His expertise in operations and management led him to the Genetics Institute, Inc., a pioneering biotechnology company later acquired by Wyeth. This trajectory through established corporations and biotech innovators equipped him with a broad understanding of the sector's commercial and scientific challenges.

Leadership at Biogen

Mullen joined Biogen in 1989 as Vice President of Manufacturing. He ascended to the role of Chief Operating Officer in 1995 and was appointed President and Chief Executive Officer in 1998, succeeding James L. Vincent. During his tenure as CEO, which lasted until 2010, he guided the company through a transformative era. A key strategic move was engineering the 2003 merger with IDEC Pharmaceuticals, which created Biogen Idec and brought the blockbuster oncology drug Rituxan into its portfolio. Under his leadership, the company achieved major commercial success with the launch of the multiple sclerosis therapies Avonex and Tysabri, despite the latter's temporary market withdrawal due to safety concerns. Mullen also navigated the company through significant corporate challenges, including a proxy contest with investor Carl Icahn.

Later career and board memberships

Following his departure from Biogen, Mullen assumed the role of Chief Executive Officer at Patheon, a global pharmaceutical contract development and manufacturing organization, from 2011 to 2014. He has held prominent positions on the boards of directors for numerous life sciences and healthcare companies. His board service has included roles at Alkermes plc, Achillion Pharmaceuticals, and the medical device company ICU Medical. He has also served on the board of the biotechnology firm Sangamo Therapeutics and contributed his expertise to the National Academy of Engineering.

Personal life

Mullen maintains a relatively private personal life. He has been involved with various philanthropic and industry organizations throughout his career. His professional achievements have been recognized with several awards and honors from academic and industry institutions.